21801-80-9

Basic information

• Product Name: 7-Methylimidazo(1,2-a)pyridine-3-carboxylicacid
• Synonyms: 7-Methylimidazo(1,2-a)pyridine-3-carboxylicacid;IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-Methyl-
• CAS NO: 21801-80-9
• Molecular Formula: C₉H₈N₂O₂
• Molecular Weight: 176.17202
• Mol File: 21801-80-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.35g/cm³
• Refractive Index: 1.653
• Storage Temp.: 2-8°C
• PKA: -0.59±0.41(Predicted)
• CAS DataBase Reference: 7-Methylimidazo(1,2-a)pyridine-3-carboxylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methylimidazo(1,2-a)pyridine-3-carboxylicacid(21801-80-9)
• EPA Substance Registry System: 7-Methylimidazo(1,2-a)pyridine-3-carboxylicacid(21801-80-9)

Safety Data

• Hazardous Substances Data: 21801-80-9(Hazardous Substances Data)

Usage

General Description

7-Methylimidazo(1,2-a)pyridine-3-carboxylic acid, also known as 7-MeIgP-3-CA, is a chemical compound that belongs to the class of heterocyclic aromatic amines. It is formed during the cooking process of meat and fish at high temperatures, particularly through grilling or barbecuing. 7-MeIgP-3-CA has been identified as a potentially hazardous compound, as it has been classified as a Group 2B carcinogen by the International Agency for Research on Cancer. This means that it is possibly carcinogenic to humans. Research has shown that 7-MeIgP-3-CA may be linked to an increased risk for certain types of cancer, including colorectal and prostate cancer. As a result, efforts have been made to reduce human exposure to this compound, particularly by promoting healthier cooking methods and the consumption of less processed meats.

InChI:InChI=1/C9H8N2O2/c1-6-3-2-4-11-7(9(12)13)5-10-8(6)11/h2-5H,1H3,(H,12,13)

Upstream product

• 1397228-36-2 7-methyl-imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester 

Downstream Products

• 1426654-03-6 methyl 4-fluoro-3-(7-methylimidazo[1,2-a]pyridine-3-carboxamido)benzoate 
• 1426653-21-5 N-(2-fluoro-5-(((1S,2S)-1-hydroxy-3-methoxy-1-phenylpropan-2-yl)carbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide 
• 1426653-22-6 N-(5-(((1S,2S)-1,3-dihydroxy-1-phenylpropan-2-yl)carbamoyl)-2-fluorophenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide 
• 1426654-02-5 4-fluoro-3-(7-methylimidazo[1,2-a]pyridine-3-carboxamido)benzoic acid 
• 1426666-71-8 N-(5-(5-(3-hydroxy-3-methylbutyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine-3-carboxamide 
• 1426667-50-6 (R)-7-methyl-N-(2-methyl-5-(5-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426667-47-1 (S)-7-methyl-N-(2-methyl-5-(5-(4,4,4-trifluoro-3-hydroxy-3-methylbutyl)-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426671-35-3 7-methyl-N-(2-methyl-5-(5-(3-oxobutyl)-1,2,4-oxadiazol-3 yl)phenyl)imidazo[1,2-]pyridine-3-carboxamide 
• 1426133-24-5 methyl 3-(3-(4-methyl-3-(7-methylimidazo[1,2-a]pyridine-3-carboxamido)phenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 

Relevant articles and documents

SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.